Phase
Condition
Pancreatic Cancer
Pancreatic Disorders
Treatment
Therapeutic Colonoscopy
Resection
Questionnaire Administration
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Patients that are seen at MD Anderson Cancer Center
Patients with pancreatic ductal adenocarcinoma (PDAC) diagnosis who are expected tohave surgery (Whipple)
Adequate hematological function, defined by white blood cell (WBC) count ≥ 3,000/microL, platelet count ≥75,000/microL, and Hgb ≥ 8 g/dL
Adequate hepatic function defined by a total bilirubin level ≤ 1.5 × the upper limitof normal (ULN), an AST, level ≤ 2.5 × ULN, and an ALT level ≤ 2.5 × ULN
Adequate renal function defined by an estimated creatinine clearance >30 mL/minaccording to the Cockcroft-Gault formula or by a creatinine clearance measurementfrom a 24-hour urine collection
Age 18 years and above
Male or female
Willingness and ability to sign an informed consent
Consent and ability to give blood and stool samples
Consent to undergo a baseline core biopsy and colonoscopy for FMT delivery
An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
Exclusion
Exclusion Criteria:
Age younger than 18 years
Positive GI infection
Patients with pancreatic cancer Stage T1N0
Individuals at higher risk of colonization with MDROs
Patient received antibiotics in the last 48 hours. Patients will be eligible toenroll if antibiotic therapy is discontinued for at minimum 48 hours prior to startof study
Patients with active viral, bacterial or fungal infection
History of inflammatory bowel disease, and/or radiation enteritis or colitis
Pregnant and breastfeeding women
Women of child-bearing potential who have positive urine or serum pregnancy test orrefuse to do pregnancy test
Has a diagnosis of immunodeficiency
Peripheral WBC >12 x 10^9/L and/or temperature >38 degrees Celsius
Subjects with neutropenia (ANC <1500)
Swallowing dysfunction or known chronic aspiration
Delayed gastric emptying
History of intestinal obstruction
Acute exacerbation of underlying comorbid condition
Severely immunocompromised patients
Allergies to drugs included as part of trial (antibiotics, loperamide or laxatives)
Study Design
Study Description
Connect with a study center
M D Anderson Cancer Center
Houston, Texas 77030
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.